Want to see PODD full AI Analyst Report?
Top Page
Insulet
(NASDAQ:PODD)
Select Model
Select Model
Rating:68Neutral
Price Target:
$153.00
▲(6.96% Upside)
Action:Reiterated
Date:09/22/26
PODD scores as a solid fundamental growth company (strong revenue growth, high gross margins, improving operating profitability and balance-sheet de-risking) reinforced by upbeat EPS and international-growth guidance from the latest earnings call. The overall score is held back primarily by weak technicals (price below major moving averages with negative MACD) and some execution/cash-flow risks highlighted on the call (type 2 retention issues and modestly lower free cash flow outlook), while valuation appears reasonable for a growth profile but not distinctly cheap.
Positive Factors
Recurring consumable revenue model
The disposable Omnipod model creates recurring revenue as patients replace pods regularly, supporting visibility beyond one-time hardware sales. This repeat usage can strengthen customer retention, improve planning, and provide a durable foundation for continued growth as the installed base expands.
Negative Factors
Type 2 retention execution risk
Weak onboarding and first-90-day retention among type 2 customers could reduce the lifetime value of new users and make growth investments less efficient. Although management describes the issue as addressable, corrective actions must improve utilization before this customer segment becomes a durable growth contributor.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumable revenue model
The disposable Omnipod model creates recurring revenue as patients replace pods regularly, supporting visibility beyond one-time hardware sales. This repeat usage can strengthen customer retention, improve planning, and provide a durable foundation for continued growth as the installed base expands.
Read all positive factors
Insulet Key Performance Indicators (KPIs)
Any
Revenue by Segment
Provides insight into which business segments are driving sales, highlighting areas of strength and potential growth within the company's operations.
Provides insight into which business segments are driving sales, highlighting areas of strength and potential growth within the company's operations.
Data provided by:
The Fly
The FlyInsulet (PODD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.13B
Dividend YieldN/A
Average Volume (3M)1.70M
Price to Earnings (P/E)24.6
Beta (1Y)0.34
Revenue Growth29.41%
EPS Growth59.39%
CountryUS
Employees5,400
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)5.36
Shares Outstanding69,354,200
10 Day Avg. Volume1,574,804
30 Day Avg. Volume1,703,204
Financial Highlights & Ratios
PEG Ratio-1.97
Price to Book (P/B)13.20
Price to Sales (P/S)7.38
P/FCF Ratio52.94
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue3.60
Enterprise Value/Gross Profit5.06
Enterprise Value/Ebitda17.24
Forecast
1Y Price Target
$164.43Price Target Upside14.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
EPS Forecast (FY)6.5
Revenue Forecast (FY)$3.29B
Insulet Business Overview & Revenue Model
Company Description
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin...
How the Company Makes Money
Insulet primarily makes money by selling its Omnipod insulin delivery system through a recurring, disposable-based model. The largest revenue driver is the ongoing sale of Omnipod pods—single-use, wearable, tubeless insulin delivery devices that p...
Insulet Earnings Call Summary
Earnings Call Date:Aug 05, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 04, 2026
Earnings Call Sentiment Positive
The call conveyed a broadly positive operational and financial performance — strong revenue, significant margin expansion, robust EPS growth, international strength, product and clinical progress, and solid liquidity — while transparently acknowledging a meaningful, addressable execution issue in onboarding and retaining type 2 customers that led to a modest downward revision to U.S. revenue outlook and a reassessment of longer-term assumptions. Management presented concrete actions (expanded customer care, sales compensation changes, sampling refinements, Omnipod Discover and data platform investments) to remediate retention and utilization in the first 90 days and expressed confidence these will translate into improved outcomes over time.Positive Updates
Strong Revenue Growth
Q2 total revenue of $802 million, up 23.5% reported and 22.7% constant currency year-over-year; company delivered another quarter of strong top-line growth.
Negative Updates
Type 2 Retention and Utilization Challenges
Observed lower-than-expected utilization and retention among type 2 customers, especially pronounced in Q2; company attributes the issue to onboarding/first-90-day execution rather than product or pricing.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Revenue Growth
Q2 total revenue of $802 million, up 23.5% reported and 22.7% constant currency year-over-year; company delivered another quarter of strong top-line growth.
Read all positive updates
Company Guidance
Insulet updated 2026 guidance to expect full‑year constant‑currency total company revenue growth of 20–22% and total Omnipod growth of 21–23%, with U.S. Omnipod up 17–19% and international Omnipod up 30–32% (FX expected to add ~100 bps to total/company Omnipod growth and ~300 bps to international); Q3 guidance calls for Omnipod growth of 18–20% and total company growth of 17.5–19.5% (U.S. Omnipod 14–16%, international Omnipod 28–30%) with FX headwinds of ~50 bps to Q3 totals and ~200 bps to international, management still expects ~100 bps of operating‑margin expansion in 2026, roughly $40M of net interest expense, a non‑GAAP tax rate of 20–21%, ~70M shares outstanding, adjusted EPS growth of at least 30% for the year, free cash flow modestly down versus 2025 (YTD FCF $145M) and an exit‑rate into year‑end in the mid‑teens constant‑currency that the company aims to meet or exceed in 2027 (preliminary view assumes competition but not benefits from newly deployed retention actions).Insulet Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
74
Positive
Cash Flow
71
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.05B | 2.71B | 2.07B | 1.70B | 1.31B | 1.10B |
| Gross Profit | 2.17B | 1.94B | 1.45B | 1.16B | 805.60M | 752.10M |
| EBITDA | 636.90M | 532.30M | 423.70M | 323.60M | 109.00M | 139.60M |
| Net Income | 375.30M | 247.10M | 418.30M | 206.30M | 4.60M | 16.80M |
Balance Sheet | ||||||
| Total Assets | 3.17B | 3.19B | 3.09B | 2.59B | 2.25B | 2.05B |
| Cash, Cash Equivalents and Short-Term Investments | 534.90M | 716.10M | 953.40M | 704.20M | 674.70M | 791.60M |
| Total Debt | 948.40M | 1.05B | 1.42B | 1.45B | 1.43B | 1.29B |
| Total Liabilities | 1.74B | 1.68B | 1.88B | 1.86B | 1.77B | 1.49B |
| Stockholders Equity | 1.42B | 1.52B | 1.21B | 732.70M | 476.40M | 556.30M |
Cash Flow | ||||||
| Free Cash Flow | 298.30M | 377.70M | 305.40M | 70.10M | -38.30M | -190.80M |
| Operating Cash Flow | 511.20M | 569.30M | 430.30M | 145.70M | 119.00M | -68.10M |
| Investing Cash Flow | -248.90M | -222.70M | -146.20M | -119.40M | -191.10M | -82.70M |
| Financing Cash Flow | -845.40M | -595.30M | -28.10M | -13.60M | -40.30M | 40.70M |
Insulet Technical Analysis
Negative
143.05
Price Trends
145.24
Negative
149.41
Negative
193.38
Negative
Market Momentum
-3.81
Positive
35.82
Neutral
14.89
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PODD, the sentiment is Negative. The current price of 143.05 is above the 20-day moving average (MA) of 137.07, below the 50-day MA of 145.24, and below the 200-day MA of 193.38, indicating a bearish trend. The MACD of -3.81 indicates Positive momentum. The RSI at 35.82 is Neutral, neither overbought nor oversold. The STOCH value of 14.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PODD.
Insulet Risk Analysis
Insulet disclosed 36 risk factors in its most recent earnings report. Insulet reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Insulet Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $110.49B | 21.12 | 10.60% | 3.31% | 9.77% | 12.28% | |
76 Outperform | $32.21B | 32.96 | 36.19% | ― | 15.54% | 77.43% | |
73 Outperform | $168.71B | 31.35 | 10.52% | 2.54% | 8.06% | -61.33% | |
68 Neutral | $9.13B | 24.57 | 26.69% | ― | 29.41% | 59.39% | |
62 Neutral | $1.02B | -11.29 | -26.30% | ― | 52.54% | 2.69% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $1.15B | -17.77 | -45.97% | ― | 3.92% | 70.03% |
* Healthcare Sector Average
PODD
Insulet
131.69
-180.00
-57.75%
ABT
Abbott Laboratories
97.50
-33.22
-25.41%
DXCM
Dexcom
85.36
19.00
28.63%
MDT
Medtronic
86.38
-8.89
-9.33%
TNDM
Tandem Diabetes Care
16.50
1.49
9.93%
BBNX
Beta Bionics, Inc.
18.96
-2.99
-13.62%
Insulet Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Insulet Amends Credit Facilities, Expands Revolving Commitments
Positive
Sep 21, 2026
On September 21, 2026, Insulet Corporation amended its existing credit agreement, replacing $475 million of outstanding term loans with an equal amount of new term loans at lower interest rate margins. The new loans, issued at par, along with cash...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
Insulet Introduces New Executive Deferred Compensation Plan
Positive
Sep 16, 2026
On September 14, 2026, Insulet’s Talent and Compensation Committee approved a Nonqualified Deferred Compensation Plan, effective January 1, 2027, for a select group of management and highly compensated employees under ERISA, including named ...
Executive/Board Changes
Insulet announces upcoming director resignations amid transitions
Neutral
Sep 10, 2026
On September 3, 2026, longtime director and former chairman Timothy J. Scannell stepped down from Insulet’s board for health reasons, ending a 12-year tenure that included seven years as chairman during a period of substantial growth and adv...
Business Operations and StrategyExecutive/Board Changes
Insulet Appoints Jay Mazelsky to Board of Directors
Positive
Jun 25, 2026
On June 24, 2026, Insulet’s board appointed Jonathan “Jay” Mazelsky as a Class II independent director, effective July 1, 2026, with plans for him to stand for election at the 2027 annual shareholders’ meeting. As a non-emp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.